MCID: MLG076
MIFTS: 38

Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Categories: Cancer diseases, Endocrine diseases, Reproductive diseases

Aliases & Classifications for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

MalaCards integrated aliases for Malignant Ovarian Surface Epithelial-Stromal Neoplasm:

Name: Malignant Ovarian Surface Epithelial-Stromal Neoplasm 12 15
Malignant Ovarian Surface Epithelial-Stromal Tumor 73

Classifications:



External Ids:

Disease Ontology 12 DOID:2151
NCIt 50 C40026
UMLS 73 C1518236

Summaries for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Disease Ontology : 12 An ovary epithelial cancer that has material basis in epithelial and stromal tissue and arises from the surface epithelium of the ovary.

MalaCards based summary : Malignant Ovarian Surface Epithelial-Stromal Neoplasm, also known as malignant ovarian surface epithelial-stromal tumor, is related to malignant ovarian brenner tumor and ovarian carcinosarcoma. An important gene associated with Malignant Ovarian Surface Epithelial-Stromal Neoplasm is TP53 (Tumor Protein P53), and among its related pathways/superpathways are GPCR Pathway and TGF-Beta Pathway. The drugs Fentanyl and Dehydroepiandrosterone have been mentioned in the context of this disorder. Affiliated tissues include ovary, lung and kidney, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Diseases related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 219)
# Related Disease Score Top Affiliating Genes
1 malignant ovarian brenner tumor 11.5
2 ovarian carcinosarcoma 11.5
3 breast reconstruction 10.4 BRCA1 BRCA2
4 nosophobia 10.4 BRCA1 BRCA2
5 gastric papillary adenocarcinoma 10.4 ERBB2 TP53
6 cancerophobia 10.4 BRCA1 BRCA2
7 breast medullary carcinoma 10.4 BRCA1 ERBB2
8 adult hepatocellular carcinoma 10.4 PIK3CA TP53
9 cerebral convexity meningioma 10.4 CDH1 TP53
10 vulvar intraepithelial neoplasia 10.4 KRT7 TP53
11 breast cystic hypersecretory carcinoma 10.4 CDH1 ERBB2
12 cerebellar angioblastoma 10.4 TP53 WT1
13 krukenberg carcinoma 10.4 HNF1B KRT7
14 large intestine adenocarcinoma 10.4 CDH1 KRT7
15 linitis plastica 10.4 CDH1 KRT7
16 bladder benign neoplasm 10.4 KRT7 PAX8
17 hyperplastic polyposis syndrome 10.3 KRAS TP53
18 nephrogenic adenoma of urinary bladder 10.3 KRT7 PAX8
19 benign mesothelioma 10.3 KRT7 WT1
20 li-fraumeni syndrome 10.3 BRCA1 BRCA2 TP53
21 intracranial chondrosarcoma 10.3 CEACAM5 TP53
22 hereditary breast ovarian cancer syndrome 10.3 BRCA1 BRCA2 TP53
23 intracystic papillary adenoma 10.3 CEACAM5 ERBB2
24 gallbladder squamous cell carcinoma 10.3 CEACAM5 ERBB2
25 esophageal adenosquamous carcinoma 10.3 CDH1 CEACAM5
26 mucinous adenofibroma 10.3 CEACAM5 KRT7
27 anus adenocarcinoma 10.3 CEACAM5 KRT7
28 cutaneous mucoepidermoid carcinoma 10.3 CEACAM5 KRT7
29 anal gland adenocarcinoma 10.3 CEACAM5 KRT7
30 sweat gland cancer 10.3 ERBB2 KRT7 TP53
31 hereditary site-specific ovarian cancer syndrome 10.3 BRCA1 BRCA2
32 laryngeal squamous cell carcinoma 10.3 CDH1 TP53 VEGFA
33 pancreatic ductal carcinoma 10.3 KRT7 TP53 VEGFA
34 grade iii astrocytoma 10.3 MMP2 TP53 VEGFA
35 dysgerminoma of ovary 10.3 BRCA1 BRCA2 WT1
36 sigmoid neoplasm 10.3 CEACAM5 KRAS
37 tuberculous salpingitis 10.3 BRCA1 BRCA2 ERBB2
38 oropharynx cancer 10.3 CDH1 KRT7 TP53
39 thymus cancer 10.3 KRT7 PAX8 TP53
40 urachal adenocarcinoma 10.3 CEACAM5 KRAS
41 nervous system cancer 10.3 AKT1 TP53 VEGFA
42 central nervous system cancer 10.3 AKT1 TP53 VEGFA
43 laryngeal disease 10.3 CDH1 MMP2 TP53
44 tongue cancer 10.3 CDH1 MMP2 TP53
45 oral cancer 10.3 CDH1 MMP2 TP53
46 barrett's adenocarcinoma 10.3 ERBB2 KRAS TP53
47 synchronous bilateral breast carcinoma 10.3 BRCA1 BRCA2 TP53
48 dysgerminoma 10.3 BRCA1 KRT7 WT1
49 adenomyosis 10.3 CDH1 MMP2 VEGFA
50 fallopian tube adenocarcinoma 10.3 BRCA1 BRCA2 ERBB2

Graphical network of the top 20 diseases related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm:



Diseases related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Symptoms & Phenotypes for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

GenomeRNAi Phenotypes related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm according to GeneCards Suite gene sharing:

26 (show all 34)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.92 WT1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.92 ARID1A
3 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.92 WT1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.92 BRCA1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.92 BRCA1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.92 WT1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.92 HNF1B
8 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.92 PAX8
9 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.92 ARID1A BRCA1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.92 ARID1A
11 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.92 HNF1B
12 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.92 BRCA1 HNF1B
13 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.92 ARID1A
14 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.92 ARID1A
15 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.92 HNF1B WT1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.92 WT1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.92 PAX8
18 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.92 PAX8
19 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.92 WT1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.92 WT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.92 PAX8
22 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.92 ARID1A BRCA1 HNF1B PAX8 WT1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.92 WT1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.92 HNF1B
25 Increased shRNA abundance (Z-score > 2) GR00366-A-5 9.92 HNF1B
26 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.92 BRCA1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.92 BRCA1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.92 ARID1A
29 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.92 HNF1B
30 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.92 HNF1B
31 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.92 PAX8
32 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.92 WT1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.92 PAX8
34 Decreased viability in esophageal squamous lineage GR00235-A 9.77 ARID1A BRCA1 BRCA2 CDH1 ERBB2 HNF1B

MGI Mouse Phenotypes related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm:

46 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.48 ACSBG1 AKT1 AREG ARID1A BRCA1 BRCA2
2 endocrine/exocrine gland MP:0005379 10.44 ACSBG1 AKT1 AREG ARID1A BRCA1 BRCA2
3 growth/size/body region MP:0005378 10.43 AKT1 AREG ARID1A BRCA1 BRCA2 CDH1
4 cardiovascular system MP:0005385 10.42 AKT1 AREG ARID1A BRCA1 CDH1 ERBB2
5 cellular MP:0005384 10.41 AKT1 ARID1A BRCA1 BRCA2 CDH1 ERBB2
6 embryo MP:0005380 10.39 AKT1 ARID1A BRCA1 BRCA2 CDH1 ERBB2
7 mortality/aging MP:0010768 10.37 AKT1 AREG ARID1A BRCA1 BRCA2 CDH1
8 immune system MP:0005387 10.35 AKT1 AREG ARID1A BRCA1 BRCA2 CDH1
9 neoplasm MP:0002006 10.23 AKT1 ARID1A BRCA1 BRCA2 CDH1 ERBB2
10 integument MP:0010771 10.22 AKT1 AREG BRCA1 BRCA2 CDH1 ERBB2
11 muscle MP:0005369 10.22 AKT1 ARID1A BRCA1 ERBB2 HNF1B KRAS
12 digestive/alimentary MP:0005381 10.19 AREG BRCA1 BRCA2 CDH1 ERBB2 KRAS
13 nervous system MP:0003631 10.17 AKT1 ARID1A BRCA1 BRCA2 ERBB2 KRAS
14 normal MP:0002873 10.15 AKT1 ARID1A BRCA1 BRCA2 CDH1 ERBB2
15 craniofacial MP:0005382 10.14 ARID1A ERBB2 KRAS MMP2 PAX8 TP53
16 reproductive system MP:0005389 10.1 ACSBG1 AKT1 AREG ARID1A BRCA1 BRCA2
17 no phenotypic analysis MP:0003012 10.06 ARID1A CDH1 ESS2 KRAS PAX8 PIK3CA
18 limbs/digits/tail MP:0005371 10.05 BRCA1 BRCA2 ERBB2 KRAS PAX8 TP53
19 renal/urinary system MP:0005367 9.92 BRCA1 HNF1B KRAS KRT7 PAX8 TP53
20 respiratory system MP:0005388 9.76 AKT1 BRCA1 ERBB2 KRAS MMP2 TP53
21 skeleton MP:0005390 9.7 AKT1 ARID1A BRCA1 BRCA2 ERBB2 KRAS
22 vision/eye MP:0005391 9.23 AREG ARID1A KRAS MMP2 PAX8 PIK3CA

Drugs & Therapeutics for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Drugs for Malignant Ovarian Surface Epithelial-Stromal Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 114)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 5881
3 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
4 Cola Phase 3,Phase 1,Phase 2,Not Applicable
5 Central Nervous System Depressants Phase 3
6 Adjuvants, Anesthesia Phase 3
7 Liver Extracts Phase 3,Phase 1,Not Applicable
8 Anesthetics, Intravenous Phase 3
9 Analgesics, Opioid Phase 3
10 Peripheral Nervous System Agents Phase 3
11 Anesthetics, General Phase 3
12 Analgesics Phase 3
13 Narcotics Phase 3
14 Anesthetics Phase 3
15 Adjuvants, Immunologic Phase 3,Phase 2
16 Immunologic Factors Phase 3,Phase 2,Phase 1
17 DHEA (Dehydroepiandrosterone) Phase 3
18
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
19
Paclitaxel Approved, Vet_approved Phase 2,Phase 1,Not Applicable 33069-62-4 36314
20
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
21
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
22
Fondaparinux Approved, Investigational Phase 2 104993-28-4
23
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
24
Etoposide Approved Phase 2 33419-42-0 36462
25
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
26
Amifostine Approved, Investigational Phase 2,Phase 1 20537-88-6 2141
27
Ifosfamide Approved Phase 2 3778-73-2 3690
28
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
29
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 6055-19-2, 50-18-0 2907
30
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
31
Serine Approved, Nutraceutical Phase 2 56-45-1 5951
32
Squalamine Investigational Phase 2 148717-90-2
33
Oblimersen Experimental, Investigational Phase 1, Phase 2 190977-41-4
34 Anti-Bacterial Agents Phase 2,Phase 1
35 Angiogenesis Modulating Agents Phase 2,Phase 1
36 Anti-Infective Agents Phase 2,Phase 1
37 Protective Agents Phase 2,Phase 1
38 Angiogenesis Inhibitors Phase 2,Phase 1
39 Antineoplastic Agents, Phytogenic Phase 2,Phase 1,Not Applicable
40 Antimitotic Agents Phase 2,Phase 1,Not Applicable
41 Albumin-Bound Paclitaxel Phase 2,Phase 1,Not Applicable
42 Mitogens Phase 2,Phase 1
43 Immunoglobulin G Phase 2,Phase 1
44 Immunoglobulins Phase 2,Phase 1
45 Antibodies, Monoclonal Phase 2,Phase 1
46 Endothelial Growth Factors Phase 2,Phase 1
47 Antibodies Phase 2,Phase 1
48 Poly(ADP-ribose) Polymerase Inhibitors Phase 2
49 Serine Proteinase Inhibitors Phase 2
50
protease inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 53)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms Active, not recruiting NCT01376349 Phase 3 prasterone
3 Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian Cancer Unknown status NCT00021385 Phase 2 carboplatin;squalamine lactate
4 Nutritional Supplements in Improving Quality of Life During First-Line Chemotherapy in Patients With Metastatic Gynecological Cancer Unknown status NCT00905658 Phase 2
5 Paclitaxel in Treating Patients With Ovarian Stromal Cancer Completed NCT00006227 Phase 2 Paclitaxel
6 Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer Completed NCT01764802 Phase 2
7 Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary Completed NCT00748657 Phase 2
8 Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies Completed NCT01079832 Phase 2
9 Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer Completed NCT00664781 Phase 2 rucaparib (CO-338; formally AG-014699 or PF-01367338)
10 Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer Completed NCT00381888 Phase 2 fondaparinux sodium
11 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
12 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2 docetaxel
13 High-dose ICE With Amifostine Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
14 Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect Completed NCT00003425 Phase 1, Phase 2 amifostine trihydrate;cyclophosphamide;melphalan
15 Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer Withdrawn NCT00562185 Phase 1, Phase 2 carboplatin;doxorubicin hydrochloride
16 Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer Completed NCT01652794 Phase 1 carboplatin;gemcitabine hydrochloride
17 Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors Completed NCT00408655 Phase 1 paclitaxel;carboplatin;temsirolimus
18 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1 7-hydroxystaurosporine;irinotecan hydrochloride
19 Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery Completed NCT00842452 Phase 1 topotecan hydrochloride
20 Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer Completed NCT00287885 Phase 1 docetaxel
21 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1 vorinostat
22 Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor Completed NCT00161187 Phase 1
23 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00083213 Phase 1
24 Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00082823 Phase 1
25 Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors Completed NCT00006036 Phase 1 cisplatin;lurtotecan liposome
26 Chemotherapy Plus Radiation Therapy in Treating Patients With Unresectable, Residual, or Recurrent Colorectal Cancer Completed NCT00003704 Phase 1 capecitabine
27 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Completed NCT00002901 Phase 1 docetaxel
28 PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer Completed NCT00055705 Phase 1
29 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
30 LMB-9 Immunotoxin in Treating Patients With Advanced Colon, Breast, Non-small Cell Lung, Bladder, Pancreatic, or Ovarian Cancer Completed NCT00005858 Phase 1
31 Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer Completed NCT00005807 Phase 1 BMS-247550
32 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1 tanespimycin
33 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Recruiting NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
34 Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer Withdrawn NCT00118300 Phase 1 capecitabine
35 Study of Genes and the Environment in Patients With Ovarian Cancer in the East Anglia, Oxford, Trent, or West Midlands Regions of the United Kingdom Unknown status NCT00757263
36 Study of DNA Mutations in Predicting the Effect of External-Beam Radiation Therapy in Patients With Early Breast Cancer, Localized Prostate Cancer, or Gynecological Cancer Unknown status NCT00601406 Not Applicable
37 Studying Genes in Samples From Younger Patients With Ovarian or Testicular Sex Cord Stromal Tumors Completed NCT01572467
38 Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Completed NCT01080521
39 Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Completed NCT01126346 Not Applicable
40 Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer Completed NCT01764789 Not Applicable
41 Collecting Tumor Samples From Patients With Gynecological Tumors Completed NCT00897442
42 Study of Physical and Psychosocial Rehabilitation Needs of Patients After Diagnosis and Treatment of Upper Gastrointestinal Cancer or Gynecological Cancer Completed NCT01216813
43 Low-Fiber Diet or High-Fiber Diet in Preventing Bowel Side Effects in Patients Undergoing Radiation Therapy for Gynecological Cancer, Bladder Cancer, Colorectal Cancer, or Anal Cancer Completed NCT01170299 Not Applicable
44 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919
45 Incidence of Blood Clots in Patients Undergoing Chemotherapy for Solid Tumors Completed NCT00433602
46 Improving Employment in Patients Who Have Survived Cervical Cancer, Uterine Cancer, or Ovarian Cancer Completed NCT00383279 Not Applicable
47 Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer Completed NCT00295945 fentanyl citrate;hydromorphone hydrochloride;ropivacaine hydrochloride
48 Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer Completed NCT00253708 Not Applicable
49 Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients Completed NCT00253383 Not Applicable
50 Radiolabeled Folic Acid and Imaging to Detect Ovarian Cancer Completed NCT00003763 Not Applicable

Search NIH Clinical Center for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Genetic Tests for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Anatomical Context for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

MalaCards organs/tissues related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm:

41
Ovary, Lung, Kidney, Colon, Pancreas, Thyroid, Thymus

Publications for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Variations for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Expression for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Search GEO for disease gene expression data for Malignant Ovarian Surface Epithelial-Stromal Neoplasm.

Pathways for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Pathways related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm according to GeneCards Suite gene sharing:

(show top 50) (show all 77)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 AKT1 AREG BRCA1 BRCA2 ERBB2 KRAS
2
Show member pathways
13.54 AKT1 AREG BRCA1 CDH1 ERBB2 HNF1B
3
Show member pathways
13.53 AKT1 ERBB2 HNF1B KRAS KRT7 MMP2
4
Show member pathways
13.41 AKT1 ERBB2 KRAS MMP2 PIK3CA PSMA2
5
Show member pathways
13.33 AKT1 AREG CDH1 ERBB2 KRAS PSMA2
6
Show member pathways
13.06 AKT1 CDH1 KRAS PSMA2 TP53 VEGFA
7
Show member pathways
13.01 AKT1 AREG BRCA1 ERBB2 KRAS PIK3CA
8 12.8 AKT1 AREG ERBB2 KRAS TP53 VEGFA
9
Show member pathways
12.78 AKT1 CDH1 KRAS PIK3CA VEGFA
10
Show member pathways
12.76 AKT1 ERBB2 KRAS PIK3CA PSMA2 TP53
11
Show member pathways
12.75 AKT1 CDH1 ERBB2 KRAS PIK3CA TP53
12
Show member pathways
12.72 AKT1 KRAS MMP2 PIK3CA VEGFA
13
Show member pathways
12.72 AKT1 ARID1A BRCA1 BRCA2 CDH1 ERBB2
14
Show member pathways
12.62 AKT1 ERBB2 KRAS MMP2 PIK3CA TP53
15
Show member pathways
12.6 AKT1 AREG BRCA2 CDH1 ERBB2 KRAS
16
Show member pathways
12.56 AKT1 ERBB2 KRAS PIK3CA TP53
17 12.56 BRCA1 ERBB2 KRAS PIK3CA TP53 VEGFA
18
Show member pathways
12.52 AKT1 AREG CDH1 ERBB2 KRAS MMP2
19
Show member pathways
12.49 AKT1 ERBB2 KRAS PIK3CA TP53
20 12.48 AKT1 CDH1 HNF1B PSMA2 TP53
21
Show member pathways
12.47 AKT1 AREG ERBB2 KRAS PIK3CA TP53
22 12.46 AKT1 KRAS PIK3CA TP53
23
Show member pathways
12.44 AREG CDH1 ERBB2 KRAS PIK3CA
24
Show member pathways
12.44 AKT1 BRCA1 KRAS PIK3CA VEGFA
25 12.38 AKT1 BRCA2 CDH1 ERBB2 KRAS MMP2
26
Show member pathways
12.36 AKT1 ERBB2 KRAS PIK3CA
27
Show member pathways
12.3 AKT1 KRAS TP53 VEGFA
28
Show member pathways
12.3 AKT1 BRCA1 PSMA2 TP53
29 12.3 AKT1 ERBB2 KRAS MMP2 PIK3CA TP53
30
Show member pathways
12.28 AKT1 AREG KRAS VEGFA
31
Show member pathways
12.26 AKT1 ERBB2 KRAS PIK3CA TP53
32 12.23 AKT1 KRAS PIK3CA TP53
33
Show member pathways
12.22 AKT1 KRAS PIK3CA TP53
34 12.2 AKT1 CDH1 KRAS MMP2 TP53 VEGFA
35
Show member pathways
12.19 AKT1 ERBB2 KRAS PIK3CA
36
Show member pathways
12.19 AKT1 KRAS PIK3CA TP53
37
Show member pathways
12.17 AKT1 ERBB2 MMP2 PIK3CA
38 12.17 AKT1 ERBB2 KRAS PIK3CA TP53
39 12.13 AKT1 MMP2 PIK3CA TP53 VEGFA
40 12.12 AKT1 KRAS PIK3CA TP53
41 12.11 MMP2 PSMA2 TP53 VEGFA
42
Show member pathways
12.11 AKT1 AREG BRCA1 CDH1 KRAS PIK3CA
43 12.1 AKT1 BRCA1 BRCA2 CDH1 KRAS TP53
44
Show member pathways
12.09 AKT1 ERBB2 PIK3CA TP53
45 12.07 AKT1 KRAS PIK3CA TP53
46 12.05 AKT1 KRAS PIK3CA TP53
47
Show member pathways
12.03 AKT1 CDH1 HNF1B PSMA2 TP53
48 12.03 AKT1 MMP2 TP53 VEGFA
49 12.03 AKT1 ERBB2 KRAS PIK3CA TP53
50
Show member pathways
11.99 AKT1 BRCA1 BRCA2 CDH1 ERBB2 KRAS

GO Terms for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

Cellular components related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.8 AKT1 AREG ARID1A BRCA1 BRCA2 ERBB2
2 cytoplasm GO:0005737 9.5 ACSBG1 AKT1 AREG BRCA1 BRCA2 CDH1

Biological processes related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.93 AKT1 AREG BRCA2 ERBB2 TP53
2 negative regulation of apoptotic process GO:0043066 9.87 AKT1 CEACAM5 ERBB2 HNF1B TP53 VEGFA
3 positive regulation of protein phosphorylation GO:0001934 9.86 AKT1 ERBB2 KRAS VEGFA
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.8 AREG TP53 VEGFA
5 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.8 AKT1 PIK3CA VEGFA
6 liver development GO:0001889 9.79 HNF1B KRAS PIK3CA
7 response to glucocorticoid GO:0051384 9.77 ACSBG1 AREG KRAS
8 positive regulation of MAP kinase activity GO:0043406 9.76 ERBB2 KRAS VEGFA
9 epidermal growth factor receptor signaling pathway GO:0007173 9.7 AKT1 AREG PIK3CA
10 kidney development GO:0001822 9.67 HNF1B PAX8 VEGFA WT1
11 cytokine-mediated signaling pathway GO:0019221 9.63 AKT1 KRAS MMP2 PIK3CA TP53 VEGFA
12 anoikis GO:0043276 9.61 AKT1 PIK3CA
13 cellular response to gonadotropin stimulus GO:0071371 9.59 PAX8 WT1
14 phosphatidylinositol 3-kinase signaling GO:0014065 9.58 AKT1 ERBB2 PIK3CA
15 mesonephric tubule development GO:0072164 9.57 HNF1B PAX8
16 positive regulation of gene expression GO:0010628 9.56 AKT1 BRCA1 ERBB2 HNF1B KRAS TP53
17 pronephros development GO:0048793 9.55 HNF1B PAX8
18 cellular response to indole-3-methanol GO:0071681 9.51 BRCA1 CDH1
19 metanephric epithelium development GO:0072207 9.49 PAX8 WT1
20 metanephric S-shaped body morphogenesis GO:0072284 9.48 PAX8 WT1
21 chordate embryonic development GO:0043009 9.46 BRCA1 BRCA2
22 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.43 HNF1B PAX8
23 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.43 BRCA1 BRCA2 TP53
24 positive regulation of transcription, DNA-templated GO:0045893 9.28 AKT1 ARID1A BRCA1 BRCA2 CDH1 HNF1B
25 positive regulation of transcription by RNA polymerase II GO:0045944 10.12 AKT1 BRCA1 HNF1B PAX8 TP53 VEGFA
26 nervous system development GO:0007399 10.01 AKT1 ARID1A ERBB2 ESS2 VEGFA

Molecular functions related to Malignant Ovarian Surface Epithelial-Stromal Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region DNA binding GO:0044212 9.35 BRCA1 HNF1B PAX8 TP53 WT1
2 identical protein binding GO:0042802 9.23 AKT1 BRCA1 BRCA2 CDH1 CEACAM5 ERBB2
3 protein binding GO:0005515 10.11 AKT1 AREG ARID1A BRCA1 BRCA2 CDH1

Sources for Malignant Ovarian Surface Epithelial-Stromal Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....